Breaking News

Excision BioTherapeutics Secures Licenses for CRISPR Gene Editors

The editors are to be used to treat certain viral infections and infectious diseases

Excision BioTherapeutics, a company focused on the development and commercialization of advanced gene editing therapeutics for the treatment of life-threatening disease caused by viruses, has secured exclusive licenses from UC Berkeley for their newly discovered CRISPR gene editors.   They are the first company to secure licenses to further explore these gene editors as they relate to infectious diseases, including HSV, HBV, HTLV-1, in order to explore possible treatments and/or cures. T...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters